Formed in 1997, Phage Therapeutics, Inc. (PhageTx) is a United States corporation dedicated to the discovery, development and regulatory approval of bacteriophage products for the treatment of antibiotic-resistant and other bacterial infectious diseases. PhageTx is already proving itself to be a leader in this field.
PhageTx has made significant progress with its top product candidate - a bacteriophage biopharmaceutical agent being developed to treat antibiotic-resistant strains of Staphylococcus aureus (Staph) and other Staph species, the primary bacteria that cause hospital-acquired Staph infections. The emerging product has successfully completed a manufacturing development program, and formal pre-clinical testing has begun. PhageTx is also currently developing bacteriophage products for two other antibiotic-resistant infectious agents, namely, Mycobacterium tuberculosis (Tuberculosis or TB, and the multi-drug-resistant forms of TB known as MDRTB) and Pseudomonas aeruginosa.
back to top
